Henrik Krüpper Becomes New CEO of Unither Pharmaceuticals
Unither Pharmaceuticals welcomes Henrik Krüpper as Chief Executive Officer of the Group, starting May 4. He succeeds Eric Goupil, who has led the Group for more than 25 years and will continue to provide support in his new role as Chairman.
Henrik Krüpper’s appointment marks the next phase in Unither’s growth journey and forms part of a planned succession process. The Group’s priorities, culture and long-term objectives remain focused on innovation and delivering high-quality solutions that meet clients’ manufacturing needs, particularly in Blow-Fill-Seal products and liquid stick-packs.
Henrik Krüpper holds an engineering degree from RWTH Aachen, Germany. He brings over 25 years of experience across the specialty chemicals and pharmaceuticals sectors. Prior to joining Unither, he served since 2023 as Chief Operating Officer of the Drug Substances division at Swiss CDMO Siegfried Group. He previously held executive leadership positions, notably as CEO of HCS Group, and started his career in the chemical industry at Evonik (Degussa).
Unither Pharmaceuticals is a pharmaceutical contract manufacturer specialized in sterile and non-sterile liquid forms, including single-doses, multi-doses, vials, liquid stick packs, and sprays. Incumbent CEO Eric Goupil remains fully committed to Unither and will continue to support the Group in his new capacity as Chairman. Under Eric’s leadership, Unither has experienced sustained growth and strengthened its industrial footprint in France, the United States, Brazil and China, serving international clients worldwide. The Group has established itself as the global leader in Blow-Fill-Seal unit-dose technology, with an annual production capacity of 5 billion doses.
In January of 2026, the pharmaceutical group has launched the construction of a new industrial facility at its Gannat (Allier) site. This project represents a total investment of more than €140 million and will lead to the creation of 133 direct jobs by 2028, and nearly 250 jobs by 2030. It aims to strengthen France’s production capacities for sterile medical devices, in line with an industrial reshoring strategy, healthcare sovereignty, and local economic development.
